Dimensional Fund Advisors LP Increases Holdings in Insulet Co. (NASDAQ:PODD)

Dimensional Fund Advisors LP boosted its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 42.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 289,507 shares of the medical instruments supplier's stock after purchasing an additional 86,505 shares during the period. Dimensional Fund Advisors LP owned approximately 0.41% of Insulet worth $75,588,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. SBI Securities Co. Ltd. bought a new stake in shares of Insulet in the 4th quarter valued at about $36,000. SRS Capital Advisors Inc. lifted its position in Insulet by 43.1% in the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock valued at $49,000 after purchasing an additional 56 shares during the last quarter. Friedenthal Financial purchased a new stake in shares of Insulet during the fourth quarter valued at approximately $57,000. Assetmark Inc. grew its holdings in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock worth $69,000 after purchasing an additional 246 shares during the last quarter. Finally, Blue Trust Inc. increased its stake in shares of Insulet by 117.3% in the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after buying an additional 149 shares during the period.

Insider Buying and Selling at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of Insulet stock in a transaction on Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company's stock, valued at approximately $888,525. This trade represents a 36.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.47% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

PODD has been the topic of a number of recent analyst reports. Barclays raised their price target on shares of Insulet from $234.00 to $266.00 and gave the stock an "equal weight" rating in a report on Wednesday. Canaccord Genuity Group raised their target price on Insulet from $304.00 to $324.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Royal Bank of Canada assumed coverage on Insulet in a research report on Thursday, March 6th. They set an "outperform" rating and a $340.00 price target for the company. Raymond James reiterated an "outperform" rating and issued a $328.00 price objective (up from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Stifel Nicolaus upped their target price on Insulet from $245.00 to $293.00 and gave the company a "hold" rating in a report on Friday, February 21st. Five equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $293.94.

Insulet Stock Up 2.7 %

Shares of PODD traded up $6.76 during mid-day trading on Friday, reaching $257.01. The company had a trading volume of 838,676 shares, compared to its average volume of 717,346. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The company has a market capitalization of $18.05 billion, a price-to-earnings ratio of 44.39, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30. The firm has a 50-day moving average price of $257.51 and a 200 day moving average price of $262.48. Insulet Co. has a 52 week low of $160.19 and a 52 week high of $289.46.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. On average, sell-side analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.